KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Net Income (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Net Income for 8 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 124.32% to -$2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.1 million through Dec 2025, down 232.22% year-over-year, with the annual reading at -$24.2 million for FY2025, 232.41% down from the prior year.
  • Net Income hit -$2.3 million in Q4 2025 for Castle Biosciences, down from -$501000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $9.6 million in Q4 2024 to a low of -$29.2 million in Q1 2023.
  • Historically, Net Income has averaged -$8.4 million across 5 years, with a median of -$5.6 million in 2021.
  • Biggest five-year swings in Net Income: tumbled 1039.38% in 2023 and later surged 471.71% in 2024.
  • Year by year, Net Income stood at -$13.4 million in 2021, then crashed by 54.08% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then tumbled by 124.32% to -$2.3 million in 2025.
  • Business Quant data shows Net Income for CSTL at -$2.3 million in Q4 2025, -$501000.0 in Q3 2025, and $4.6 million in Q2 2025.